A landmark 503A peptide review is now officially underway. The FDA announced on April 16, 2026, that its Pharmacy Compounding Advisory Committee will convene July 23–24 to evaluate whether seven peptide substances—including BPC-157, KPV, and TB-500—merit inclusion on the Section 503A bulk drug substances list. If approved, licensed compounding pharmacies could legally compound these peptides for individual patient prescriptions for the first time since the FDA placed them in Category 2 in September 2023.
Table of Contents
The announcement, published in the Federal Register (Docket No. FDA-2025-N-6895), opens a public comment period through July 22, 2026, and initiates a formal 503A peptide review that marks the most significant regulatory development for research peptides since the original Category 2 restrictions took effect nearly three years ago.
Why This 503A Peptide Review Matters
This 503A peptide review centers on the bulk drug substances list, which determines which active pharmaceutical ingredients licensed compounding pharmacies may use to prepare medications for individual patients. To qualify, a substance must meet FDA evaluation criteria: adequate studies of safety and efficacy, absence of significant safety concerns, sufficient manufacturing controls, and demonstrated clinical need.
In September 2023, the FDA added 19 peptides to Category 2—effectively banning compounding pharmacies from working with them. The agency cited immunogenicity risks (peptides can trigger anti-drug antibodies with repeated injection), manufacturing impurity concerns (endotoxin contamination, truncated sequences, diastereomers), and the absence of robust human clinical data for most compounds.
That decision pushed peptide access almost entirely into the research chemical market—unregulated, unmonitored, and subject to none of the quality controls that 503A and 503B pharmacies provide. The irony was not lost on clinicians or patients: the FDA restricted access through the most regulated channel while the least regulated channel remained wide open.
This July meeting is the first formal step toward potentially reversing that position for seven of those 19 compounds.
The 503A Peptide Review: Which Compounds Are Under Evaluation
The PCAC will evaluate seven peptide substances across two days, each in both free base and acetate forms. Here is what the FDA’s nomination process lists as the intended clinical applications—and how the evidence actually lines up.
July 23: BPC-157, KPV, TB-500, and MOTs-C
BPC-157 (nominated for ulcerative colitis). BPC-157 has one of the most extensive preclinical portfolios of any research peptide—more than 100 rodent injury models showing consistent acceleration of tissue repair across tendons, ligaments, muscle, bone, and gut epithelium. The human evidence is far thinner: three studies exist, two in inflammatory bowel disease (oral formulation) and one in distal radial fracture healing, none of them controlled trials. Peptidings rates BPC-157 as Tier 3 (Pilot/Limited Human Data) with a Reasonable Bet verdict. The nomination for ulcerative colitis aligns with the strongest thread in its human evidence, though “strongest” here means two uncontrolled studies.
KPV (nominated for wound healing and inflammatory conditions). KPV is a tripeptide derived from alpha-melanocyte-stimulating hormone with anti-inflammatory properties demonstrated primarily in cell culture and animal models. No controlled human trials exist. Peptidings rates KPV as Tier 4 (Preclinical Only) with a Thin Ice verdict. The gap between community enthusiasm and published evidence is among the widest for any peptide on this list.
TB-500 (nominated for wound healing). TB-500 is a synthetic fragment of Thymosin Beta-4 (Tβ4), a naturally occurring protein involved in cell migration and tissue repair. The evidence base is almost entirely preclinical, and the critical distinction between TB-500 (the fragment) and full-length Tβ4 (which has more extensive research) is frequently conflated. Peptidings rates TB-500 as Tier 4 (Preclinical Only) with an Eyes Open verdict.
MOTs-C (nominated for obesity and osteoporosis). MOTs-C is a mitochondria-derived peptide involved in metabolic regulation. It has generated significant research interest for its role in exercise mimicry and metabolic homeostasis, with preclinical data in obesity and bone density models. Human data are limited to observational studies correlating endogenous MOTs-C levels with metabolic outcomes—no interventional human trials of exogenous MOTs-C have been published. Peptidings rates MOTs-C as Tier 3 (Pilot/Limited Human Data) with an Eyes Open verdict.
July 24: Emideltide, Semax, and Epitalon
Emideltide (nominated for opioid withdrawal, chronic insomnia, and narcolepsy). Emideltide is delta sleep-inducing peptide (DSIP), a neuropeptide first isolated in 1977. It has a longer research history than most peptides on this list, with several small human studies examining sleep architecture, though methodological quality varies significantly. The nominations span three distinct clinical applications—a breadth that reflects the compound’s unclear mechanism of action more than its clinical validation.
Semax (nominated for cerebral ischemia, migraine, and trigeminal neuralgia). Semax is a synthetic analogue of ACTH(4-10) with neuroprotective and nootropic properties. It holds regulatory approval in Russia for stroke recovery and cognitive disorders, which gives it a unique position among these nominees—it is the only compound on the list with any form of governmental approval for clinical use, albeit outside Western regulatory frameworks. Peptidings rates Semax as Tier 3 with a Reasonable Bet verdict.
Epitalon (nominated for insomnia). Epitalon is a synthetic tetrapeptide studied primarily by a single research group (Khavinson’s lab) for its effects on telomerase activation and pineal function. The evidence base is narrow and concentrated, with limited independent replication. Peptidings rates Epitalon as Tier 3 with an Eyes Open verdict.
The Bigger Picture: Five More Peptides in February 2027
This 503A peptide review in July is not the end of the story. The FDA has scheduled a second PCAC meeting for February 2027 to evaluate five additional peptides: LL-37 (Cathelicidin), GHK-Cu, Dihexa, Melanotan II, and PEG-MGF. Together, the two meetings will address 12 of the 19 peptides placed in Category 2 in 2023.
This phased approach—seven in July, five in February—signals that the 503A peptide review is proceeding methodically rather than issuing a blanket reversal. Each compound will be evaluated individually against the 503A criteria, and the PCAC’s recommendations are advisory, not binding. The FDA retains final decision-making authority.
The Political Context
This 503A peptide review does not exist in a regulatory vacuum. HHS Secretary Robert F. Kennedy Jr. has publicly advocated for loosening peptide restrictions, stating he is “a big fan” of peptides and arguing the FDA’s 2023 Category 2 designations were improper. He previewed this regulatory direction during a podcast appearance with Joe Rogan.
The MAHA (Make America Healthy Again) movement, which Kennedy champions, has been vocal about peptide access as a health freedom issue. This framing has made peptide regulation a political football—which creates a risk that the science gets drowned out by the politics on both sides.
Critics have raised legitimate concerns. Dr. Peter Lurie, former FDA official now at the Center for Science in the Public Interest, has warned that allowing compounding of peptides without adequate clinical testing creates a “profound threat” to the FDA’s drug-vetting system. Dr. Eric Topol of Scripps Research has stated plainly: “These peptides have no data to support their safety and efficacy.”
The Dutch Uncle position—the one Peptidings takes—is that both sides are partly right and partly wrong. The 2023 Category 2 decision was blunt: it treated peptides with extensive preclinical portfolios (BPC-157) identically to those with almost no published data. It also pushed users from regulated compounding pharmacies into the unregulated research chemical market, which is not a safety win by any metric. At the same time, political enthusiasm for peptides is running ahead of the evidence. The fact that a compound is popular does not make it safe or effective, and loosening restrictions without requiring adequate clinical data would set a dangerous precedent.
The best outcome of this 503A peptide review is one where the PCAC evaluates each compound on its own merits—preclinical evidence, human data, manufacturing feasibility, clinical need—and makes recommendations that reflect the actual state of the science, not the political winds.
How to Submit Public Comments
As part of this 503A peptide review, the FDA has opened Docket No. FDA-2025-N-6895 for public comment. Comments submitted by July 9, 2026, may be presented at the meeting; the final deadline is July 22, 2026, at 11:59 p.m. ET.
Comments can be submitted electronically at regulations.gov (search for docket FDA-2025-N-6895) or by mail to Dockets Management Staff, 5630 Fishers Lane, Rockville, MD 20852.
Persons wishing to make oral presentations at the meeting must register by June 30, 2026, by contacting Takyiah Stevenson at the FDA’s Center for Drug Evaluation and Research.
The meeting will be held in person at FDA’s White Oak Campus in Silver Spring, Maryland, and will also be accessible via online teleconference.
What This Means for You
If you currently use any of these peptides: Nothing changes immediately as a result of this 503A peptide review. The PCAC meeting is advisory—it produces recommendations, not decisions. Even a favorable PCAC vote does not automatically add a substance to the 503A list. The FDA’s final determination will follow separately, on a timeline the agency has not specified. Sourcing these compounds from research chemical suppliers remains in the same legal gray area it has been in since September 2023.
If you are a clinician: The 503A peptide review comment period is your opportunity to provide clinical evidence and patient experience data. The PCAC evaluates nominations partly on demonstrated clinical need—documented clinical use cases carry weight.
If you are watching the evidence: Peptidings will cover every stage of this 503A peptide review in real time. We will report what the nominators present, what the committee members ask, how the votes fall, and what it means for each compound’s evidence picture. Bookmark this page—we will link updated coverage here as it develops.
What does not change regardless of the outcome: The evidence base for each compound is what it is. A favorable PCAC recommendation does not make a Tier 4 compound suddenly well-studied. A 503A listing means a compounding pharmacy can legally work with the substance—it does not mean the substance is FDA-approved, clinically validated, or appropriate for any specific condition. Peptidings’ evidence tiers and verdicts reflect the published science, not the regulatory status, and they will be updated only when the science changes.
This article was published April 17, 2026. Peptidings will provide updated coverage as the July 23–24 PCAC meeting approaches and after the proceedings conclude.
References
1. FDA. “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List.” Federal Register, April 16, 2026. Federal Register
2. FDA. “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.” FDA.gov
3. PBS NewsHour. “FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters.” PBS.org
4. RAPS. “FDA considers adding a dozen peptides to its bulk drug compounding list.” RAPS.org
This is what happened. Want to know what it means?
The Peptidings newsletter delivers evidence-based analysis of peptide news—every Monday morning. No hype. No hedging. Just the Dutch Uncle's honest take.